The list includes 49 medications for chronic conditions and 51 for acute care, with an aim of informing efforts to improve supply chain reliability, according to a March 4 news release from the nonprofit organization.
The analysis, based on data from sources including the USP Medicine Supply Map, found that 71% of the drugs identified as the most vulnerable are injectables, including sodium chloride injection, dextrose injection, heparin sodium injection, propofol and lidocaine hydrochloride injection.
The report also highlights that while 61% of the medicines listed were not in shortage as of January 2025, they remain at high risk of shortage.
